FDA Grants Rare Pediatric Disease Designation to 177Lu-omburtamab-DTPA for Medulloblastoma
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company concentrated on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer; ...
FDA Grants Rare Pediatric Disease Designation to Papillon Therapeutics’ PPL-001 for Friedreich’s Ataxia
Papillon Therapeutics Inc., a clinical-stage biotechnology company focused on developing multi-systemic genetic medicines to address the root causes of inherited diseases, has announced that the U.S. ...
FLAG Therapeutics’ FLAG-003 Receives Rare Pediatric Disease Designation from FDA for Diffuse Intrinsic Pontine Glioma (DIPG) Treatment
FLAG Therapeutics announces FLAG-003 granted Rare Pediatric Disease designation by FDA. FLAG-003 is an investigational therapy for treating Diffuse Intrinsic Pontine Glioma (DIPG), a rare, aggressive ...